Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment?

Presented by:
Natalie S. Callander
Search for other papers by Natalie S. Callander in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 18: Issue 12.5
Online Publication Date:
07 Dec 2020
DOI:
https://doi.org/10.6004/jnccn.2020.5043
Restricted access

Smoldering multiple myeloma represents approximately 10% to 15% of all myeloma cases, but more thorough evaluation may decrease that number in the future. Risk stratification is important in this patient population to avoid overtreatment or undertreatment. Patients with low-risk disease can be observed without treatment, but those at higher-risk should be enrolled on clinical trials. If a clinical trial is not an option in these patients, a time-limited intervention with lenalidomide ± dexamethasone can be considered.

Disclosures: Dr. Callander has disclosed that she has no relevant financial relationships.

Correspondence: Natalie S. Callander, MD, University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Madison, WI 53792. Email: nsc@medicine.wisc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Kyle R, Elveback LR. Management and prognosis of multiple myeloma. Mayo Clin Proc 1976;51:751–760.

  • 2.

    Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–548.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–2592.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ravindran A, Bartley AC, Holton SJ, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 2016;6:e486.

  • 5.

    Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356:2582–2590.

  • 6.

    Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27:941–946.

  • 7.

    Waxman AJ, Mick R, Garfall AL, et al. Classifying ultra-high risk smoldering myeloma. Leukemia 2015;29:751–753.

  • 8.

    Zamagni E, Nanni C, Gay F, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016;30:417–422.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    San Miguel J, Mateos MV, Gonzalez V, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 8000.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 2017;31:130–135.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Calcinotto A, Brevi A, Chesi M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 2018;9:4832.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 2018;9:3363.

  • 14.

    Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol 2020;38:1126–1137.

  • 15.

    Mailankody S, Kazandjian D, Korde N, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv 2017;1:1911–1918.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Mateos MV, Lopez JM, Rodrigues-Otero P, et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HGT-ASCT, consolidation with KRd and maintenance with Rd [abstract]. Blood 2017;130(Suppl 1):Abstract 402.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 2020;34:1840–1852.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Kristinsson SY, Holmberg E, Blimark C, et al. Treatment for high-risk smoldering myeloma. N Engl J Med 2013;369:1762–1763.

Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
20 Dec 2020
Online Publication Date:
07 Dec 2020

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2602 1305 255
PDF Downloads 524 81 17
EPUB Downloads 0 0 0